公司資料
Syndax Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- SNDX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
19.76 USD (-0.40%)
收盤價
最後更新: 2026年8月17日
1.63B USD
市值
股價為何變動
As of Aug 17, 2026, SNDX closed down 0.40% at $19.76. No new same-company headline was identified in the current news window.
公司概覽
Commercial Oncology Portfolio
Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo.
Revuforj
Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers. Ongoing studies evaluate frontline combinations, post-transplant maintenance and additional molecular subgroups, including NPM1-mutant, KMT2A-rearranged and NUP98-rearranged disease.
Niktimvo
Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease. Syndax is testing the molecule in newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis to expand beyond its initial indication.
Frontline Registrational Strategy
Syndax is advancing pivotal trials intended to establish revumenib in frontline acute myeloid leukemia. It also plans the RAVEN study as part of the asset’s broader development program.
未來催化劑
- New revumenib real-world, frontline and post-transplant maintenance data expected in the second quarter of 2026.
- Additional revumenib data presentations from ongoing studies during the second half of 2026.
- Initiation of the RAVEN trial expected in the second half of 2026.
- Topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic GVHD expected in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。